Welcome to our dedicated page for enGene Therapeutics news (Ticker: engnw), a resource for investors and traders seeking the latest updates and insights on enGene Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect enGene Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of enGene Therapeutics's position in the market.
enGene Therapeutics (Nasdaq: ENGN) will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026.
The company said it plans a BLA submission for detalimogene in 2H 2026 and is targeting a potential approval in 2027, while the LEGEND trial continues including a pivotal BCG‑unresponsive NMIBC with CIS cohort.
Trading symbols remain ENGN and ENGNW; new CUSIPs and ISINs for shares and warrants will take effect on the name change.
Summary not available.